Related Experiment Videos
Zonisamide clinical trials: European experience
1Epilepsy Unit, Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland G11 6NT, UK. mjb2k@clinmed.gla.ac.uk
Seizure
|October 30, 2004
Summary
Zonisamide significantly reduced partial seizures in European clinical trials. This adjunctive therapy demonstrated sustained efficacy and good tolerability in patients with refractory epilepsy.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Refractory partial seizures pose a significant challenge in epilepsy management.
- Adjunctive therapies are crucial for improving seizure control in patients with inadequate response to monotherapy.
Purpose of the Study:
- To evaluate the efficacy and safety of zonisamide as adjunctive therapy for refractory partial seizures in European patients.
- To assess the long-term maintenance of seizure reduction and tolerability of zonisamide.
Main Methods:
- A 12-week double-blind, placebo-controlled study followed by an open-label extension of up to 18 months.
- Patients (n=144) were randomized to zonisamide (400 mg QD) or placebo.
- Efficacy was measured by median percent reduction in seizure frequency and proportion of patients achieving ≥50% reduction.
Main Results:
- Zonisamide treatment resulted in a significantly greater median percent reduction in partial seizures compared to placebo (31.6% vs. 3.3%, P=0.008).
- More zonisamide patients achieved ≥50% seizure reduction (30.4% vs. 14.7%, P=0.03).
- Efficacy was maintained or improved during the open-label extension, with zonisamide well-tolerated (mild to moderate adverse events).
Conclusions:
- Zonisamide is a safe and effective adjunctive therapy for refractory partial seizures.
- Findings align with previous trials in the US and Asia, supporting its global utility.
- Sustained seizure control and favorable tolerability profile observed in European patients.